ZTO Express (Cayman) 株価情報 (NYSE: ZTO)

最新ニュース ZTO Express (Cayman) (NYSE:ZTO) 株価情報

ZTO Express (Cayman)

ZTO Express is China's largest express delivery company by parcel volume, with a volume share of 22.1% in 2022. It operates a network partner model where it provides line-haul transportation and sorting services, while its local network partners provide first-mile pickup and last-mile delivery services under the ZTO brand name. Headquartered in Shanghai, the company was founded in 2002 by Meisong Lai, who remains chair, CEO, and its major shareholder with 77% voting rights as of June 30, 2023. ZTO's strategic shareholder is leading China e-commerce company Alibaba Group with around an 11.7% interest.

ZTO Express (Cayman) Inc. American Depositary Shares, each representing one Class A ordinary share.

ZTO Express (Cayman) Inc

ZTO EXPRESS (CAYMAN) A by ZTO Express (Cayman) Inc.

Morgan Stanley analyst Kimberly Greenberger maintains PVH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) with a Equal-Weight and lowers the price target from $95 to $86.

News

Price Target

Analyst Ratings

Morgan Stanley Maintains Equal-Weight on PVH, Lowers Price Target to $86

Fluor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) has outperformed the market over the past 5 years by 24.38% on an annualized basis producing an average annual return of 40.62%. Currently, Fluor has a market capitalization of $6.24 billion. 
Buying $1000 In FLR: If an investor had bought $1000 of FLR stock 5 years ago, it would be worth $5,683.00 today based on a price of $37.11 for FLR at the time of writing.
<h3>Fluor's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743611098_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In Fluor 5 Years Ago Would Be Worth This Much Today

Morgan Stanley analyst Betsy Graseck maintains Northern Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRS#NASDAQ">NTRS</a>) with a Equal-Weight and lowers the price target from $136 to $132.

NTRS

Morgan Stanley Maintains Equal-Weight on Northern Trust, Lowers Price Target to $132

Morgan Stanley analyst Betsy Graseck maintains Bank of New York Mellon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>) with a Overweight and lowers the price target from $99 to $98.

Morgan Stanley Maintains Overweight on Bank of New York Mellon, Lowers Price Target to $98

<a href="https://www.wsj.com/health/healthcare/fda-novavax-covid-19-vaccine-deadline-c160454b" title="https://www.wsj.com/health/healthcare/fda-novavax-covid-19-vaccine-deadline-c160454b">https://www.wsj.com/health/healthcare/fda-novavax-covid-19-vaccine-deadline-c160454b</a>

Biotech

General

NVAX

'FDA Misses Deadline For Covid-19 Vaccine Decision' - Wall Street Journal

The 25% tariff on imported cars and parts could wipe out up to 3 million vehicle sales, slash automaker profits in half and throw the U.S. auto supply chain into chaos as manufacturers scramble to reconfigure operations in a high-stakes race against time, <a href="https://www.benzinga.com/topic/expert-ideas">according to Bank of America</a>. 
In a note shared Wednesday, research analyst John P. Babcock said President Donald Trump&#8217;s new trade action announced on March 26 would trigger significant demand destruction, higher consumer prices, and a severe blow to profitability, especially if additional parts tariffs are confirmed in May.
<h3 class="wp-block-heading">How Bad Could It Get For US Auto Sales?</h3>
The proposed tariffs—taking effect April 3—apply to all imported cars, light trucks and several critical components, including engines, transmissions, and electrical systems. According to Babcock, the industry response will be higher vehicle prices across the board.
If manufacturers pass along the full 25% tariff to consumers, BofA estimates a sales loss of 3.2 million units at the current trend rate of 16 million vehicles annually — a 20% collapse. A more conservative case, with only 15% of costs passed through, still implies a demand drop of 2.5 million units, or about 15%.
"Affordability has already been a challenge," Babcock said. "This only exacerbates the situation."
<h3 class="wp-block-heading">Can Automakers Reshore Production?</h3>
There may be limited relief for automakers with idle U.S. plant capacity. 
Bank of America estimates that more than a million vehicle assembly units could be reshored to U.S. factories with minor investments and hiring. General Motors Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) and Stellantis NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>) are best positioned for this pivot.
Yet, labor constraints, weak demand for some U.S.-built models and the logistical complexities of scaling production rapidly remain obstacles. 
Over a longer horizon, most automakers could bring production stateside, yet that would require "large capital investments" and likely further tilt the product mix toward higher-end vehicles, leaving a gap in affordable options.
Chinese automakers such as BYD Co. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>), Geely, and Xiaomi could potentially fill that gap if they establish U.S. manufacturing.
<h3 class="wp-block-heading">What's The Real Cost Of Parts Tariffs?</h3>
While full vehicle reshoring is challenging, the real pain may come from the auto parts tariffs. A final decision is expected by May 3.
Babcock outlined three scenarios: targeted tariffs on powertrain and electronics, blanket tariffs on all auto parts, or a hybrid combination.
If all parts are hit with the 25% tariff, the cost per U.S.-assembled vehicle jumps by $3,285, including $1,065 for powertrain parts, $840 for electronics, and $1,380 for other components.
That alone translates to an average price increase of 8%+, which could either be passed on to consumers or absorbed in profit margins.
In total, the industry faces a $26 billion hit under this scenario, equivalent to "halving all automaker profits in the U.S.," Babcock said.
<h3 class="wp-block-heading">Reshoring Auto Parts? Not Likely</h3>
While some optimism exists around reshoring vehicle assembly, the parts side tells a different story.
According to Babcock, reshoring auto parts manufacturing is "essentially impossible" due to high U.S. labor costs and a lack of skilled workers.
Unlike vehicle plants that may have idle capacity, parts suppliers have little to no slack in the U.S. system, leaving supply chains exposed and North American production vulnerable to disruptions.
Tariffs on powertrain components may offer a narrow path to incentivize domestic production, but anything broader risks major breakdowns in vehicle manufacturing continuity.
Read now: 
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/03/44544217/chicken-tax-2-0-bank-of-america-flags-3-million-sales-at-risk-after-auto-tariffs">Chicken Tax 2.0: Bank Of America Flags 3 Million Sales At Risk After Auto Tariffs</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Equities

Large Cap

Macro Economic Events

Econ #s

Economics

BYDDY

STLA

Trump's Auto Tariffs Could Crush Demand, Blow $26 Billion Hole In Industry Profits

Treating Bitcoin as an <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44499889/bitcoin-is-fulfilling-its-destiny-as-world-reserve-currency-says-bitcoin-whale-trace-mayer">asset of strategic importance</a> could catalyze a ripple effect for the United States, according to a report by Grayscale.
What Happened: "If the U.S. signals that it views Bitcoin and public blockchain technology as strategically important, other countries may reconsider their own approach," the report said.
This framing is part of Grayscale's broader argument that Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is evolving from a speculative investment into a geopolitical asset with long-term economic and strategic implications. 
The report points to China as a key country to watch, noting that while <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40985461/china-controls-55-of-bitcoin-hashrate-despite-crypto-ban-but-the-us-is-catching-up">China currently bans most crypto activities</a>, recent discussions by its Supreme Court and judicial bodies in February 2025 suggest a possible reevaluation of the legal treatment of digital assets.
The company noted that rising institutional interest and sovereign engagement with Bitcoin are setting the stage for a new era of competition and cooperation around decentralized technologies.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44607188/arthur-hayes-predicts-bitcoin-to-hit-250000-by-end-of-year">Arthur Hayes Predicts Bitcoin To Hit $250,000 By End Of Year</a>
"The opportunity to shape the future of public blockchain technology is not unlike the early days of the internet," Grayscale added. "Countries that dismissed it fell behind. Those that embraced it became digital leaders."
Grayscale's report outlines how the alignment of national interest with blockchain innovation could unlock substantial benefits — not just for economic growth, but also for national security and digital sovereignty. 
It also points to the growing number of state actors exploring central bank digital currencies (CBDCs) and <a href="https://www.benzinga.com/content/44557661/fbs-explores-the-us-bitcoin-reserve-and-its-market-implications">Bitcoin treasury reserves</a> as evidence of the changing tide.
However, the firm cautioned that regulatory clarity remains key to unlocking the next phase of institutional participation. 
"A coherent and proactive U.S. strategy could serve as a model globally," Grayscale stated.
The firm also highlighted the growth in stablecoins and asset tokenization as further evidence of institutional momentum. 
The total amount of tokenized assets, excluding stablecoins, hit a record $19.5 billion in March, driven largely by BlackRock's tokenized Treasury product BUIDL, which reached a market cap of nearly $2 billion.
Meanwhile, companies like Fidelity and World Liberty Financial are reportedly planning to launch Dollar-backed stablecoins, and PayPal's stablecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PYUSD</a>) now has a market cap of $725 million.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44605174/circles-revenue-grows-but-ipo-filing-shows-falling-profitability">Circle&#8217;s Revenue Grows, But IPO Filing Shows Falling Profitability</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$PYUSD

Strategic Bitcoin Embrace By US Could Trigger Global Crypto Policy Shift, Says Grayscale

<a href="https://www.c-span.org/event/senate-committee/boeing-ceo-testifies-on-aircraft-safety/432060">https://www.c-span.org/event/senate-committee/boeing-ceo-testifies-on-aircraft-safety/432060</a>
&nbsp;

Government

Regulations

Boeing CEO Says Planemaker Still Working With Justice Department On Revised Plea Agreement

Numerous public companies have updated their 2025 guidance in response to the Trump administration&#8217;s tariffs on China, Mexico and Canada, but additional tariffs on other countries could have significant impacts, DA Davidson analyst Linda Bolton Weiser warned in a <a href="https://www.benzinga.com/analyst-stock-ratings">new note to clients on Tuesday</a>.
What To Know: President Donald Trump is expected to announce tariffs on potentially trillions of dollars worth of goods imported to the U.S. on Wednesday.
The potential impacts are wide-ranging. Bolton Weiser flagged several names under her coverage umbrella that could be impacted in the Health &amp; Beauty and Leisure space. The analyst noted additional tariffs are &#8220;not reflected in estimates.&#8221;
<ul>
<li>Hasbro Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAS#NASDAQ">HAS</a>): Neutral rating; has exposure to Vietnam, India and Japan</li>
</ul>
<ul>
<li>Interparfums Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPAR#NASDAQ">IPAR</a>): Buy rating; produces in France</li>
</ul>
<ul>
<li>Funko Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNKO#NASDAQ">FNKO</a>): Buy rating; produces in Vietnam</li>
</ul>
<ul>
<li>Mattel Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAT#NASDAQ">MAT</a>): Buy rating; has exposure to Indonesia, Malaysia, Vietnam and Thailand</li>
</ul>
<ul>
<li>Helen of Troy Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HELE#NASDAQ">HELE</a>): Neutral rating; produces in Vietnam</li>
</ul>
<ul>
<li>e.l.f. Beauty Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>): Neutral rating; produces in Thailand</li>
</ul>
<ul>
<li>1-800-FLOWERS.COM Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLWS#NASDAQ">FLWS</a>): Neutral rating; buys cut flowers from Colombia and Equador</li>
</ul>
Trump is expected to announce reciprocal tariffs on several countries at a White House event at 4 p.m. ET. The Trump administration has said the tariffs could target specific sectors.
The tariff announcements have created uncertainty across markets with the S&amp;P 500 crossing into correction territory last month. The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was up 0.46% at $563.55 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The SPY is still down about 4% year-to-date and well off its highs from February.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44609012/etsy-how-severely-will-trumps-tariffs-weigh-on-demand">Etsy: How Severely Will Trump&#8217;s Tariffs Weigh On Demand?</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/Jack_the_sparow">Jack_the_sparow</a>/Shutterstock.

FLWS

FNKO

HELE

IPAR

Tariff Risk Increases: Analyst Warns Of Additional Impact On Hasbro, Funko, Mattel, E.L.F. Beauty — 'Not Reflected In Estimates'

<figure class="wp-block-image size-large"><img decoding="async" src="https://thearorareport.com/wp-content/uploads/2025/04/2025-04-02_08h10_37.jpg" alt="" /></figure>
<h4 class="wp-block-heading">Gold Outshines</h4>
Please <a href="https://thearorareport.com/stock-market-chart-analysis-gold-outperforms-tech-stocks-gld-qqq-mc-04022025">click here</a> for an enlarged chart comparing Invesco QQQ Trust Series 1 (QQQ), SPDR S&amp;P 500 ETF Trust (SPY) which represents the benchmark stock market index S&amp;P 500 (SPX), iShares Bitcoin Trust ETF (IBIT), and SPDR Gold Trust (GLD).
Note the following:
<ul>
<li>The chart shows that for this volatile period since the peak in tech stocks, gold has outperformed as follows:
<ul>
<li>Gold has outperformed SPY by 15.02%.</li>
<li>Gold has outperformed QQQ, which represents tech stocks, by 18.13%.</li>
<li>Gold has outperformed bitcoin ETF (IBIT) by 19.93%.</li>
</ul>
</li>
<li>As full disclosure, Gold ETF (GLD) is in our ZYX Allocation Model Portfolio.  In the Core Model Portfolio, allocation to GLD has been 5% &#8211; 8%.   In the Lower Exposure Model Portfolio, the allocation to GLD has been 4% &#8211; 6%.   In addition, there is also a GLD trade around position in our ZYX Allocation – the allocation to precious metals has been 5% &#8211; 8% of the portfolio. </li>
<li>As full disclosure and as a reference, allocation to bitcoin ETF (IBIT) has been 0% &#8211; 2% in our ZYX Allocation Core Model Portfolio and 0% in the Lower Exposure Model Portfolio.  Further, partial profits have been taken three times on IBIT, leaving only a very small position in our Model Portfolio.</li>
<li>For the period shown on the chart, bitcoin volatility is about 300% that of gold.&nbsp; Prudent investors focus on risk adjusted returns.&nbsp; Risk adjusted returns on bitcoin must be significantly higher than gold to match the return in gold.</li>
<li>The chart is also very instructive in that Wall Street's consensus at the beginning of the chart period was the total opposite of what has happened.&nbsp;&nbsp;</li>
<li>President Trump is scheduled to make a tariff announcement today at 4pm ET.</li>
<li>A battle royale has been raging between stock market bulls and bears ahead of President Trump's announcement.&nbsp; Yesterday, stock market bulls got the upper hand, aided by blind money.&nbsp; In the early trade this morning, stock market bears have the upper hand.&nbsp; It is worth repeating what we shared with you yesterday:</li>
</ul>
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow"><ul>
<li>There are divergent opinions on how the stock market will behave after Trump reveals his tariff plan on Liberation Day.
<ul>
<li>Permabulls are expecting a rip-roaring rally and urging their followers to aggressively buy stocks.</li>
<li>Permabears are expecting a big market drop.</li>
</ul>
</li>
<li>In our analysis, prudent investors should ignore both the permabulls and the permabears.</li>
<li>In our analysis, how the market behaves after Trump&#8217;s reveal will come down to the difference between expectations about tariffs that are built into the market and what Trump reveals.
<ul>
<li>If the tariffs Trump reveals are less onerous than market expectations, the stock market will go up.</li>
<li>If the tariffs Trump reveals are more onerous than market expectations, the stock market will go down.</li>
</ul>
</li>
</ul>
</blockquote>
<ul>
<li>The latest ISM manufacturing data shows stagflation – growth is slowing and prices are rising.&nbsp; ISM Manufacturing Index came at 49.0% vs. 49.8% consensus.&nbsp; More importantly, Prices Paid Index came at 69.4 vs. 64 consensus.&nbsp; As a reference, the index was at 62.4 in February.</li>
<li>ADP is the largest private payroll processor in the country.&nbsp; ADP uses its data to provide a glimpse of the official jobs report, the mother of all reports, that will be released on Friday at 8:30am ET.&nbsp; The just released ADP employment change came at 155K vs. 120K consensus. &nbsp; This indicates that the jobs picture remains strong.</li>
<li>As we have shared with you before, prudent investors need to be aware that jobs data can deteriorate very quickly.&nbsp; It is important to stay alert. &nbsp;Prudent investors should also keep in mind that ADP data does not include government employees.</li>
<li>Tesla Inc (TSLA) delivery data impacts stock market sentiment.  For this reason, prudent investors should pay attention to Tesla delivery data.  Tesla produced over 362K vehicles vs. over 412K consensus and delivered over 336K vehicles vs. over 378K consensus and whisper numbers of around 360K.  As of this writing in the premarket, these numbers are negatively impacting stock market sentiment.</li>
</ul>
<h4 class="wp-block-heading">Magnificent Seven Money Flows</h4>
In the early trade, money flows are negative in Apple Inc (AAPL), Amazon.com, Inc. (AMZN), Alphabet Inc Class C (GOOG), Meta Platforms Inc (META), Microsoft Corp (MSFT), NVIDIA Corp (NVDA), and (TSLA).
In the early trade, money flows are negative in S&amp;P 500 ETF (SPY) and Nasdaq 100 ETF (QQQ).
<h4 class="wp-block-heading">Momo Crowd And Smart Money In Stocks</h4>
Investors can gain an edge by knowing money flows in SPY and QQQ.  Investors can get a bigger edge by knowing when smart money is buying stocks, gold, and oil.  The most popular ETF for gold is SPDR Gold Trust (GLD).  The most popular ETF for silver is iShares Silver Trust (SLV).  The most popular ETF for oil is United States Oil ETF (USO).
<h4 class="wp-block-heading">Bitcoin</h4>
Bitcoin is range bound.
<h4 class="wp-block-heading">Protection Band And What To Do Now</h4>
It is important for investors to look ahead and not in the rearview mirror.  Our proprietary protection band puts all of the data, all of the indicators, all of the news, all of the crosscurrents, all of the models, and all of the analysis in an analytical framework that is easily actionable by investors.
Consider continuing to hold good, very long term, existing positions. Based on individual risk preference, consider a protection band consisting of cash or Treasury bills or short-term tactical trades as well as short to medium term hedges and short term hedges. This is a good way to protect yourself and participate in the upside at the same time.
You can determine your protection bands by adding cash to hedges.&nbsp; The high band of the protection is appropriate for those who are older or conservative. The low band of the protection is appropriate for those who are younger or aggressive.&nbsp; If you do not hedge, the total cash level should be more than stated above but significantly less than cash plus hedges.
A protection band of 0% would be very bullish and would indicate full investment with 0% in cash.&nbsp; A protection band of 100% would be very bearish and would indicate a need for aggressive protection with cash and hedges or aggressive short selling.
It is worth reminding that you cannot take advantage of new upcoming opportunities if you are not holding enough cash.&nbsp; When adjusting hedge levels, consider adjusting partial stop quantities for stock positions (non ETF); consider using wider stops on remaining quantities and also allowing more room for high beta stocks.&nbsp; High beta stocks are the ones that move more than the market.
<h4 class="wp-block-heading">Traditional 60/40 Portfolio</h4>
Probability based risk reward adjusted for inflation does not favor long duration strategic bond allocation at this time.
Those who want to stick to traditional 60% allocation to stocks and 40% to bonds may consider focusing on only high quality bonds and bonds of five year duration or less.&nbsp; Those willing to bring sophistication to their investing may consider using bond ETFs as tactical positions and not strategic positions at this time.
The Arora Report is known for its accurate calls. The Arora Report correctly called the big artificial intelligence rally before anyone else, the new bull market of 2023, the bear market of 2022, new stock market highs right after the virus low in 2020, the virus drop in 2020, the DJIA rally to 30,000 when it was trading at 16,000, the start of a mega bull market in 2009, and the financial crash of 2008. Please click here to sign up for a free forever <a href="https://thearorareport.com/generate-wealth-newsletter-benzinga">Generate Wealth Newsletter</a>.

Market Summary

Opinion

Markets

Gold Outshines Tech Stocks And Bitcoin, As Bulls And Bears Battle Ahead Of Trump Tariff Announcement

Needham analyst Mike Matson reiterates Enovis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENOV#NYSE">ENOV</a>) with a Buy and maintains $64 price target.

Reiteration

ENOV

Needham Reiterates Buy on Enovis, Maintains $64 Price Target

&ldquo;My mom was dying from cancer and I wanted her off all the medications that were basically killing her,&rdquo; says <a href="https://elplanteo.com/gary-payton-cannabis-bienestar/">Gary Payton</a>, recalling the deeply personal journey that brought him to <a href="https://www.benzinga.com/cannabis">cannabis</a>. &ldquo;I wanted her to live and she wasn&rsquo;t responding to the things that I was doing. So I tried cannabis, and it brought her back. In those last days, she was able to talk, laugh, smile. I wanted to remember my mom that way,&rdquo; he shares.
Still connected to basketball&mdash;coaching, mentoring and practicing daily&mdash;Payton has now expanded his focus to a new passion: promoting cannabis for wellness. His latest venture, Greater Purpose, launched in partnership with Green Label Rx, debuted in 2024 and represents his broader mission to make cannabis accessible as a natural alternative for pain relief and recovery.
While Payton already has a globally recognized cannabis strain named after him, his relationship with the plant remains practical. &ldquo;I never smoked weed. I don&rsquo;t do it now,&rdquo; he says. &ldquo;It wasn&rsquo;t for me. But I&rsquo;ve seen what it can do for people, and that&rsquo;s why I believe in it,&rdquo; he adds, clarifying that his interest lies in cannabis&rsquo;s therapeutic potential rather than recreational use.
However, there are two people who could make him reconsider his stance on smoking weed: &ldquo;Only two people, I would probably smoke a joint with right now: Bob Marley and my mom,&rdquo; he says with a smile. For Payton, both figures symbolize a connection to cannabis rooted in peace, healing and memory&mdash;a poignant reflection on how cannabis can transcend simple use and take on a more profound meaning.
<h2>&lsquo;If You Can Get Up And Move Around, That Changes Everything&rsquo;</h2>
At the heart of Greater Purpose is a commitment to wellness, especially for athletes and those who live active lives. Payton has witnessed firsthand the relentless toll that sports can take on the body, often leaving players in pain long after their careers end. &ldquo;I see guys like Earl Campbell who can&rsquo;t walk, who can&rsquo;t get up. And I want to help,&rdquo; Payton says, emphasizing the motivation behind his wellness line. The brand&rsquo;s initial products&mdash;balms and salves&mdash;are crafted specifically to address chronic muscle pain and inflammation, common afflictions for anyone who&rsquo;s put their body through rigorous physical demands.
<img alt="Greater Purpose by Gary Payton" src="https://imageio.forbes.com/specials-images/imageserve/671ff760049e65f300923d06/Greater-Purpose-by-Gary-Payton/960x0.png?format=png&amp;width=1440" style="height:450px; width:364px" />
Greater Purpose by Gary Payton - Courtesy of Green Label Rx
&ldquo;Some people can&rsquo;t even walk a golf course,&rdquo; he continues. &ldquo;I want them to feel good, get up, and move around. When you wake up feeling bad, what does it do? It brings your whole mentality and spirit down. But if you can get up and move around, that changes everything.&rdquo; For Payton, the link between physical health and mental resilience is clear. His products are designed to support that balance, helping others find a path to both physical recovery and a renewed outlook on life.
<h2>A Family Matter</h2>
Jason McKnight, CEO and founder of Green Label Rx, shares Payton&rsquo;s commitment to wellness. The partnership with Payton is deeply personal for McKnight, who has known the basketball legend for years. &ldquo;Gary&rsquo;s like family. We&rsquo;ve been working together for a while, and this collaboration felt natural,&rdquo; McKnight explains.
Also read:&nbsp;<a class="post-card-article-link" href="https://www.benzinga.com/markets/cannabis/25/03/44535351/ice-ts-latest-hustle-a-jersey-city-cannabis-dispensary-with-a-social-justice-mission">Ice-T&#39;s Latest Hustle? A Jersey City Cannabis Dispensary With A Social Justice Mission</a>
Green Label Rx, a vertically integrated cannabis company that McKnight started with his wife in 2006, has been focused on wellness since its inception. Now, with operations in California, New Mexico and Arizona, the company is poised to take Greater Purpose national.
As the head of a social equity brand, McKnight brings a unique and personal dimension to Greater Purpose&rsquo;s mission. Reflecting on his journey, he notes, &ldquo;I&rsquo;ve been in the space for years, and the challenges we faced early on&mdash;raids, prison, separation from family&mdash;led us to become a social equity brand.&rdquo;
His experience underlines his commitment to ensuring that communities most affected by cannabis prohibition can have a stake in the industry&rsquo;s growth. &ldquo;For us, this is about more than just business&mdash;it&rsquo;s a chance to uplift others who&rsquo;ve endured similar hardships, giving back to those communities as we build our brand,&rdquo; McKnight shares. This focus on equity aligns with Greater Purpose&rsquo;s broader goal of creating meaningful change, making the brand as much a personal mission as a community-driven effort.
<h3>All About Understanding The Ailments You Seek To Address</h3>
McKnight, a former athlete, knows firsthand the importance of effective pain management. &ldquo;As I get older, I&rsquo;m dealing with my own aches and pains&mdash;knees, hips, elbows. I wanted to find something that could help with inflammation and pain without the negative side effects of pills,&rdquo; McKnight explains. The partnership with Payton was a natural step forward in their shared vision for wellness.
What sets Greater Purpose apart, McKnight explains, is a strict focus on quality from start to finish. &ldquo;We do everything in-house&mdash;from cultivation to manufacturing to retail. That means we can ensure the quality of every product that comes out with the Greater Purpose name on it,&rdquo; he states.
Designed with active lifestyles in mind, the brand&rsquo;s product line is not exclusive to athletes. &ldquo;This isn&rsquo;t just for people who play sports. It&rsquo;s for anyone who needs relief: Whether you&rsquo;re a mom chasing after kids all day, an EMT on your feet for hours, or someone dealing with the aches and pains of getting older,&rdquo; McKnight adds.
And this is only the beginning. McKnight reveals that they are already working on additional products, like sleep aids and gummies, aimed at providing relief without THC&rsquo;s psychoactive effects. Payton elaborates, &ldquo;A lot of people don&rsquo;t want that high. So we&rsquo;re creating products that are mild, things that will help people sleep or feel better without making them feel out of it.&rdquo;
Offering cannabis products that meet diverse needs is especially important to Payton as well. &ldquo;Not everyone wants to get high,&rdquo; he says, highlighting his focus on products that support wellness without unwanted side effects.
But Payton&rsquo;s mission with Greater Purpose goes beyond physical relief. &ldquo;It&rsquo;s about understanding, mental health support&hellip; I want people to live a prosperous life with cannabis, not the addiction that comes from medications,&rdquo; he emphasizes. For Payton, cannabis offers not only an alternative to pharmaceuticals but a pathway to reclaim health naturally and sustainably.
<h3>Cannabis And Sports: A Growing Trend</h3>
Payton is joining a growing group of professional athletes who have turned to cannabis as a cornerstone of their post-sports careers.&nbsp;<a href="https://www.forbes.com/sites/javierhasse/2021/10/08/nba-stars-allen-iverson-al-harrington-talk-cannabis-this-is-definitely-a-lifestyle/" target="_self" title="https://www.forbes.com/sites/javierhasse/2021/10/08/nba-stars-allen-iverson-al-harrington-talk-cannabis-this-is-definitely-a-lifestyle/">Al Harrington</a>, a former NBA player, founded the cannabis brands Viola and Village Cannabis, while&nbsp;<a href="https://www.forbes.com/sites/javierhasse/2022/09/09/wu-tang-clans-raekwon-nba-star-chris-webber-discuss-their-new-cannabis-venture-an-airbnb-model-for-cannabis/" target="_self" title="https://www.forbes.com/sites/javierhasse/2022/09/09/wu-tang-clans-raekwon-nba-star-chris-webber-discuss-their-new-cannabis-venture-an-airbnb-model-for-cannabis/">Chris Webber</a>&nbsp;co-launched a $100 million cannabis equity fund. NFL stars like Calvin Johnson and Rob Gronkowski have also embraced cannabis for recovery and pain management.
These athletes are tapping into a cannabis industry that&rsquo;s projected to grow significantly, with sales&nbsp;<a href="https://www.grandviewresearch.com/industry-analysis/us-cannabis-market" rel="nofollow noopener noreferrer" target="_blank" title="https://www.grandviewresearch.com/industry-analysis/us-cannabis-market">already exceeding</a>&nbsp;$33 billion in the U.S. and expected to reach $76 billion by 2025. For many, cannabis isn&rsquo;t just a business: it&rsquo;s a way to promote wellness and provide alternatives to pharmaceuticals, especially for pain relief.
Payton sees this trend playing out in professional sports leagues as well. &ldquo;Almost 80% of NBA players smoke marijuana,&rdquo; he says, noting that the NBA&rsquo;s decision to stop testing for cannabis marked a turning point. Athletes who were once at risk of suspension for using the plant are now free to incorporate it into their recovery routines without fear of punishment. &ldquo;You can&rsquo;t come to the game high. But if you&rsquo;re home, feeling bad after a game, and you need relief, cannabis can be that solution,&rdquo; he explains.
As the stigma around cannabis continues to lift, Payton advocates for its broader acceptance, especially in mental health. Reflecting on its potential benefits, he shares, &ldquo;They [lawmakers] have to do more research on what&rsquo;s going on&hellip; [Cannabis] helps mental health. People can smoke marijuana or a joint and calm down, think about their life, and not [about] suicide or being depressed.&rdquo; Payton&rsquo;s hope is for cannabis to be embraced not just as a pain reliever but as a wellness tool for both mind and body.
<h3>Bringing Greatness To Cannabis</h3>
For Payton, Greater Purpose is more than just a brand; it&rsquo;s part of his legacy. He&rsquo;s committed to building something that lasts, much like his impact on the basketball court. &ldquo;When I played basketball, I brought greatness to the game,&rdquo; Payton reflects. &ldquo;Now, I&rsquo;m bringing that same greatness to the cannabis industry.&rdquo;
Payton&rsquo;s passion for cannabis stems from his personal experiences, but his broader vision is to reshape how people view health and recovery. Having seen the dangers of pharmaceutical dependency firsthand with his mother&rsquo;s struggle, Payton believes cannabis offers a safer, more natural alternative.
As Greater Purpose continues to grow, both Payton and McKnight remain focused on delivering real, tangible results. &ldquo;I&rsquo;m not going to put my name on something unless I believe in it,&rdquo; Payton insists, underscoring the importance of quality in everything they produce.
<h3>A Vision For The Future: Wellness For All</h3>
With Greater Purpose&rsquo;s initial launch underway, Payton and McKnight are setting ambitious goals. Their aim is to build a national brand known for accessible, high-quality wellness products that meet diverse needs&mdash;from muscle recovery to sleep support. &ldquo;We&rsquo;re not stopping here,&rdquo; McKnight shares, emphasizing plans to expand into new markets and tap into the growing demand for non-psychoactive, CBD-based products.
While the wellness market booms, for Payton and McKnight, Greater Purpose represents more than business success; it&rsquo;s a chance to reshape perceptions. Payton, using his platform as a sports icon, hopes to advocate for cannabis as a powerful wellness tool and a means of social change. &ldquo;A lot of people are still stuck in the mindset that cannabis is just about getting high,&rdquo; Payton notes. &ldquo;But we&rsquo;re trying to show them that it&rsquo;s about healing, recovery and living a better life.&rdquo;
As Greater Purpose grows, the duo remains steadfast in their mission. &ldquo;We&rsquo;re going to keep pushing, keep innovating and keep doing right by the people who trust us,&rdquo; McKnight says.
For Payton, this journey is about leaving a lasting impact that reaches far beyond the basketball court. &ldquo;I want Greater Purpose to be remembered as one of the best cannabis brands out there,&rdquo; he reflects. &ldquo;But more than that, I want people to know we&rsquo;re here to help, to heal, and to make a real difference in people&rsquo;s lives.&rdquo;
Stay tuned for more on this and other exciting projects in the cannabis space.
Photo courtesy of&nbsp;Green Label Rx
Follow me on&nbsp;<a href="https://www.twitter.com/javierhasse" rel="nofollow noopener noreferrer" target="_blank">Twitter</a>&nbsp;or&nbsp;<a href="https://www.linkedin.com/in/javierhasse/" rel="nofollow noopener noreferrer" target="_blank">LinkedIn</a>.&nbsp;Check out&nbsp;my&nbsp;<a href="https://elplanteo.com/" rel="nofollow noopener noreferrer" target="_blank">website</a>&nbsp;or&nbsp;some of my other work&nbsp;<a href="https://benzinga.com/cannabis" rel="nofollow noopener noreferrer" target="_blank">here</a>.&nbsp;
This article was originally published on <a href="https://www.forbes.com/sites/javierhasse/2024/11/01/gary-paytons-greater-purpose-i-never-smoked-weed-cannabis-isnt-just-for-getting-high-inside-his-mission-to-promote-wellness/">Forbes</a> and appears here with permission. The article is from an external source. It does not represent Benzinga&#39;s reporting and has not been edited for content or accuracy.

Cannabis

Interview

Gary Payton Wants You To Rethink Cannabis: 'It's About Mental Health… It Brought My Mom Back In Her Final Days'

Truist Securities analyst Tobey Sommer maintains GFL Environmental (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFL#NYSE">GFL</a>) with a Buy and raises the price target from $54 to $58.

Truist Securities Maintains Buy on GFL Environmental, Raises Price Target to $58

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and maintains $500 price target.

ALNY

HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $500 Price Target

Truist Securities analyst Jordan Levy reiterates First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) with a Buy and lowers the price target from $285 to $245.

FSLR

Truist Securities Reiterates Buy on First Solar, Lowers Price Target to $245

Whales with a lot of money to spend have taken a noticeably bearish stance on Marvell Tech.
Looking at options history for Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) we detected 17 trades.
If we consider the specifics of each trade, it is accurate to state that 35% of the investors opened trades with bullish expectations and 58% with bearish.
From the overall spotted trades, 8 are puts, for a total amount of $508,879 and 9, calls, for a total amount of $380,653.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $60.0 and $95.0 for Marvell Tech, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Marvell Tech's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Marvell Tech's significant trades, within a strike price range of $60.0 to $95.0, over the past month.
<h3>Marvell Tech Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743610141_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRVL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/04/25</td>
<td>$1.87</td>
<td>$1.79</td>
<td>$1.87</td>
<td>$63.00</td>
<td>$102.8K</td>
<td>2.6K</td>
<td align="right">550</td>
</tr>
<tr>
<td>MRVL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$32.9</td>
<td>$32.85</td>
<td>$32.85</td>
<td>$95.00</td>
<td>$98.5K</td>
<td>1.3K</td>
<td align="right">30</td>
</tr>
<tr>
<td>MRVL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$6.6</td>
<td>$6.55</td>
<td>$6.6</td>
<td>$62.50</td>
<td>$87.1K</td>
<td>3.3K</td>
<td align="right">182</td>
</tr>
<tr>
<td>MRVL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$8.7</td>
<td>$8.65</td>
<td>$8.65</td>
<td>$65.00</td>
<td>$60.5K</td>
<td>528</td>
<td align="right">70</td>
</tr>
<tr>
<td>MRVL</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/21/25</td>
<td>$7.35</td>
<td>$7.25</td>
<td>$7.3</td>
<td>$75.00</td>
<td>$58.4K</td>
<td>192</td>
<td align="right">80</td>
</tr>
</tbody>
</table>

<h3>About Marvell Tech</h3>
Marvell Technology is a fabless chip designer focused on wired networking, where it has the second-highest market share. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical and copper transceivers, switches, and storage controllers.
Following our analysis of the options activities associated with Marvell Tech, we pivot to a closer look at the company's own performance.
<h3>Current Position of Marvell Tech</h3>
<ul>
<li>Currently trading with a volume of 3,403,040, the MRVL's price is down by -1.79%, now at $61.55. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 57 days.</li>
</ul>
<h3>What The Experts Say On Marvell Tech</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $118.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Keybanc continues to hold a Overweight rating for Marvell Tech, targeting a price of $115. 
&#x2A; Reflecting concerns, an analyst from Benchmark lowers its rating to Buy with a new price target of $135. 
&#x2A; An analyst from Barclays persists with their Overweight rating on Marvell Tech, maintaining a target price of $130. 
&#x2A; Maintaining their stance, an analyst from Piper Sandler continues to hold a Overweight rating for Marvell Tech, targeting a price of $95. 
&#x2A; An analyst from Stifel has decided to maintain their Buy rating on Marvell Tech, which currently sits at a price target of $115. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Marvell Tech, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

MRVL

Marvell Tech Unusual Options Activity

Digital Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLR#NYSE">DLR</a>) has outperformed the market over the past 20 years by 4.42% on an annualized basis producing an average annual return of 12.53%. Currently, Digital Realty Trust has a market capitalization of $48.82 billion. 
Buying $1000 In DLR: If an investor had bought $1000 of DLR stock 20 years ago, it would be worth $10,543.87 today based on a price of $145.03 for DLR at the time of writing.
<h3>Digital Realty Trust's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743610137_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Digital Realty Trust Stock In The Last 20 Years

Investors with a lot of money to spend have taken a bullish stance on Ceragon Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNT#NASDAQ">CRNT</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CRNT, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 10 uncommon options trades for Ceragon Networks.
This isn't normal.
The overall sentiment of these big-money traders is split between 70% bullish and 30%, bearish.
Out of all of the special options we uncovered, 2 are puts, for a total amount of $87,750, and 8 are calls, for a total amount of $490,794.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $2.0 to $4.0 for Ceragon Networks over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Ceragon Networks's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Ceragon Networks's substantial trades, within a strike price spectrum from $2.0 to $4.0 over the preceding 30 days.
<h3>Ceragon Networks Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743610136_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRNT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$0.75</td>
<td>$0.65</td>
<td>$0.74</td>
<td>$2.00</td>
<td>$73.0K</td>
<td align="right">585</td>
<td>9.0K</td>
</tr>
<tr>
<td>CRNT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$0.8</td>
<td>$0.75</td>
<td>$0.77</td>
<td>$2.00</td>
<td>$72.9K</td>
<td align="right">585</td>
<td>11.1K</td>
</tr>
<tr>
<td>CRNT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$0.75</td>
<td>$0.65</td>
<td>$0.73</td>
<td>$2.00</td>
<td>$72.4K</td>
<td align="right">585</td>
<td>9.5K</td>
</tr>
<tr>
<td>CRNT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$0.75</td>
<td>$0.55</td>
<td>$0.67</td>
<td>$2.00</td>
<td>$70.7K</td>
<td align="right">585</td>
<td>7.0K</td>
</tr>
<tr>
<td>CRNT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$0.7</td>
<td>$0.65</td>
<td>$0.68</td>
<td>$2.00</td>
<td>$69.4K</td>
<td align="right">585</td>
<td>5.0K</td>
</tr>
</tbody>
</table>

<h3>About Ceragon Networks</h3>
Ceragon Networks Ltd is a wireless transport company in terms of unit shipments and wide distribution of its business, providing high-capacity wireless connectivity solutions to markets across various industries, mainly wireless (mobile) networks service providers. Geographically the company generates the key revenue from India. The company also has presence in North America, Europe, Africa, Asia-Pacific and Middle East, and Latin America. The company's products include IP-50 Platform, IP-20 Platform, Pointlink.
After a thorough review of the options trading surrounding Ceragon Networks, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Ceragon Networks's Current Market Status</h3>
<ul>
<li>With a trading volume of 1,946,638, the price of CRNT is up by 0.85%, reaching $2.38.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 34 days from now.</li>
</ul>
<h3>What The Experts Say On Ceragon Networks</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $5.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Craig-Hallum lowers its rating to Buy with a new price target of $5.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Ceragon Networks options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

CRNT

Unpacking the Latest Options Trading Trends in Ceragon Networks

Investors with a lot of money to spend have taken a bearish stance on Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MRNA, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 20 uncommon options trades for Moderna.
This isn't normal.
The overall sentiment of these big-money traders is split between 35% bullish and 55%, bearish.
Out of all of the special options we uncovered, 13 are puts, for a total amount of $481,932, and 7 are calls, for a total amount of $328,492.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $15.0 to $70.0 for Moderna over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Moderna's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Moderna's substantial trades, within a strike price spectrum from $15.0 to $70.0 over the preceding 30 days.
<h3>Moderna Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743610130_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$5.35</td>
<td>$5.25</td>
<td>$5.25</td>
<td>$25.00</td>
<td>$85.0K</td>
<td>184</td>
<td align="right">164</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$5.35</td>
<td>$5.25</td>
<td>$5.25</td>
<td>$25.00</td>
<td>$66.6K</td>
<td>184</td>
<td align="right">166</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$4.65</td>
<td>$4.6</td>
<td>$4.6</td>
<td>$30.00</td>
<td>$53.8K</td>
<td>6.4K</td>
<td align="right">225</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$3.45</td>
<td>$3.2</td>
<td>$3.45</td>
<td>$70.00</td>
<td>$51.4K</td>
<td>760</td>
<td align="right">150</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$2.52</td>
<td>$2.51</td>
<td>$2.52</td>
<td>$22.50</td>
<td>$47.3K</td>
<td>390</td>
<td align="right">189</td>
</tr>
</tbody>
</table>

<h3>About Moderna</h3>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Having examined the options trading patterns of Moderna, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Moderna</h3>
<ul>
<li>With a volume of 4,613,675, the price of MRNA is up 4.86% at $28.48. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 29 days.</li>
</ul>
<h3>Professional Analyst Ratings for Moderna</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $36.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Citigroup downgraded its action to Neutral with a price target of $40. 
&#x2A; An analyst from JP Morgan has decided to maintain their Underweight rating on Moderna, which currently sits at a price target of $33. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Moderna options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

MRNA

Moderna Options Trading: A Deep Dive into Market Sentiment

RBC Capital analyst Shagun Singh reiterates Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Outperform and maintains $181 price target.

Comments

ZTO Express (Cayman)

ニュース

最新ニュース ZTO Express (Cayman) (NYSE:ZTO) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル